Operational MetricsThe company did not provide patient start form/PSF metrics in the press release, marking a notable departure from the norm, as this metric has been consistently reported each quarter since the product's launch in 2021.
Sales GuidanceSales guidance for FY25 is within expectations but below consensus.
Strategic OpportunitiesDisappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.